Allogene Therapeutics Announces Eric T. Schmidt, Ph.D. as Chief Financial Officer

Allogene Therapeutics, Inc. (Allogene), a biotechnology company with a
mission to catalyze the next revolution of cell therapy through the
advancement of allogeneic CAR T therapies, today announced the
appointment of Eric Schmidt, Ph.D. as Chief Financial Officer. Dr.
Schmidt comes to Allogene from Cowen and Company, where he served as
Managing Director and Senior Biotechnology Analyst since 1998. For over
two decades, Dr. Schmidt has been a highly trusted and thoughtful
industry analyst whose work has been recognized in polls conducted by
Alpha Magazine, Institutional Investor, Reuters and The Wall Street

This press release features multimedia. View the full release here:

Eric Schmidt, Ph.D., Chief Financial Officer at Allogene Therapeutics (Photo: Business Wire)

“On behalf of our Executive Chairman, Arie Belldegrun, our Board of
Directors and our entire team, it is my pleasure to welcome Eric to
Allogene,” said David Chang, M.D., Ph.D., President, Chief Executive
Officer and Co-Founder of Allogene. “Eric is an enormously talented
individual with a rare blend of insight into multiple facets of the
industry and deep relationships within the financial community. We are
very fortunate to have him join the Allogene executive team and look
forward to him applying his expertise to our vision for allogeneic cell

“Eric has been an amazing partner to the entire Cowen family for the
last 20 years,” said Jeffrey M. Solomon, Cowen CEO. “He has been part of
the lifeblood of our organization and a true friend who is passionate
about this business and our firm. I am pleased that Eric has agreed to
remain a Senior Advisor to Cowen. While we are saddened to see him leave
his current role, he does so with our health care team stronger than
ever, across research, banking, capital markets, sales, trading and
corporate access.”

Prior to joining Cowen in 1998, Dr. Schmidt was a Vice President and
Research Analyst covering the biotechnology sector for UBS Securities.
Before joining UBS, he co-founded Cambridge Biological Consultants, a
scientific consulting and research firm. He holds a B.A. in chemistry
from the University of Pennsylvania and a Ph.D. in biochemistry from the
Massachusetts Institute of Technology, where he serves on the Visiting
Committee for the Department of Biology.

“I’ve watched and analyzed dozens of companies as they worked to bring
innovative and transformative new therapies to the market,” said Dr.
Schmidt. “I have greatly admired the team and investors behind Allogene
and consider myself very fortunate to be in a position to help make a
difference in the lives of patients who are facing cancer.”

Allogene is advancing its allogeneic CAR T portfolio acquired from
Pfizer which included the rights to 16 preclinical CAR T assets licensed
from Cellectis and Servier and U.S. rights to UCART19, an allogeneic CAR
T therapy that is being developed for the treatment of CD19-expressing
hematological malignancies. In partnership with Servier, UCART19 is in
Phase 1 for the treatment of acute lymphoblastic leukemia (ALL).

About Allogene Therapeutics

Allogene Therapeutics is a biotechnology company with a mission to
catalyze the next revolution in cancer treatment through the development
of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed
at blood cancers and solid tumors. Founded and led by former Kite Pharma
executives who bring unrivaled clinical development acumen in cell
therapy, Allogene is well-positioned to further the potential of
allogeneic cell therapy for patients.

Allogeneic CAR T therapies are engineered from cells of healthy donors
and stored for “off-the-shelf” use in patients. This approach eliminates
the need to create personalized therapy from a patient’s own cells,
simplifies manufacturing, and reduces the time patients must wait for
CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell
therapy assets and UCART19, an allogeneic CAR T therapy currently in
Phase 1 development for the treatment of acute lymphoblastic leukemia
(ALL). Through its notable partnerships, Allogene leverages pioneering
technology platforms, including TALEN® gene editing
technology, to progress its portfolio of immuno-oncology
therapies. Allogene, with headquarters in San Francisco, California, is
a Two River portfolio company formed with one of the largest Series A
financings in biotechnology from an investment consortium that includes
TPG, Vida Ventures, BellCo Capital, the University of California Office
of the Chief Investment Officer, Gilead and Pfizer. For more
information, please visit www.allogene.com, and
follow @AllogeneTx on Twitter and LinkedIn.

About Cowen Inc.

Cowen Inc. is a diversified financial services firm and, together with
its consolidated subsidiaries, provides alternative asset management,
investment banking, research, sales and trading, prime brokerage, global
clearing and commission management through its two business segments:
Cowen Investment Management and its affiliates make up the Company’s
alternative investment segment, while Cowen and Company, a member of
FINRA and SIPC, and its affiliates make up the Company’s investment bank
segment. Cowen Investment Management provides alternative asset
management solutions to a global client base and manages a significant
portion of Cowen’s proprietary capital. Cowen and Company and its
affiliates offer industry focused investment banking for growth-oriented
companies, domain knowledge-driven research, a sales and trading
platform for institutional investors and a comprehensive suite of prime
brokerage services. Founded in 1918, the firm is headquartered in New
York and has offices worldwide. For additional information, visit www.cowen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005045/en/